沙库巴曲缬沙坦钠片治疗慢性心力衰竭的效果及对血清学指标的影响

Effect of Sacubitril Valsartan Sodium Tablets in the Treatment of Chronic Heart Failure and Its Influence on Serological Indexes

目的:分析与探讨沙库巴曲缬沙坦钠片治疗慢性心力衰竭的效果及对血清学指标的影响。方法:选取2017年1月-2020年1月本院收治的80例慢性心力衰竭患者作为观察对象,并回顾性分析其临床资料。将80例患者按照治疗药物的不同分为常规治疗组和沙库巴曲缬沙坦钠片治疗组,每组40例。比较两组治疗效果,治疗前后心功能水平[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、6 min步行距离、心功能NYHA分级]、血清学指标[血清生长分化因子-15(GDF-15)、可溶性基质裂解素2(sST2)、血清血管紧张素Ⅱ(AngⅡ)、血浆N末端脑钠肽前体(NT-proBNP)]及治疗期间不良反应发生情况。结果:沙库巴曲缬沙坦钠片治疗组总有效率为95.0%,高于常规治疗组的77.5%,差异有统计学意义(P<0.05)。治疗前,两组心功能水平、血清学指标比较,差异均无统计学意义(P>0.05)。治疗后,两组各项心功能指标、血清学指标均较治疗前改善,且沙库巴曲缬沙坦钠片治疗组LVEF、LVESD均高于常规治疗组,LVEDD、GDF-15、sST2、AngⅡ、NT-proBNP均低于常规治疗组,6 min步行距离长于常规治疗组,心功能NYHA分级明显优于常规治疗组,差异均有统计学意义(P<0.05)。沙库巴曲缬沙坦钠片治疗组不良反应发生率为10.0%,与常规治疗组的12.5%比较,差异无统计学意义(P>0.05)。结论:沙库巴曲缬沙坦钠片治疗慢性心力衰竭的效果较好,可有效改善心功能水平及血清学指标,且未增加用药风险,安全性较好,临床应用价值较高。

Objective:To analyze and explore the effect of Sacubitril Valsartan Sodium Tablets in the treatment of chronic heart failure and its influence on serological indexes.Method:From January 2017 to January 2020,80 patients with chronic heart failure treated in our hospital were selected as the observation objects,and their clinical data were retrospectively analyzed.According to the different drugs,80 patients were divided into the conventional treatment group and the Sacubitril Valsartan Sodium Tablets treatment group,40 cases in each group.The therapeutic effect,cardiac function levels[left ventricular ejection fraction (LVEF),left ventricular end diastolic diameter (LVEDD),left ventricular end systolic diameter (LVESD),6-min walking distance,NYHA grade of cardiac function]before and after treatment,serological indexes[serum growth differentiation factor-15 (GDF-15),soluble suppression of tumorigenicity 2 (ST2),serum angiotensin Ⅱ (AngⅡ) and Plasma N-terminal pro brain natriuretic peptide (NT-proBNP)]before and after treatment,adverse reactions during treatment were compared between two groups.Result:The total effective rate of the Sacubitril Valsartan Sodium Tablets treatment group was 95.0%,which was higher than 77.5% of the conventional treatment group,the difference was statistically significant (P<0.05).Before treatment,there were no significant differences in cardiac function and serological indexes between the two groups (P>0.05).After treatment,all cardiac function indexes and serological indexes in two groups were improved compared with those before treatment,LVEF,LVESD in the Sacubitril Valsartan Sodium Tablets treatment group were higher than those in the conventional treatment group,LVEDD,GDF-15,sST2,AngⅡ and NT-proBNP were lower than those in the conventional treatment group,the 6-min walking distance was longer than that in the conventional treatment group,and the NYHA grade of cardiac function was significantly better than that in the conventional treatment group,the differences were statistically significant (P<0.05).The incidence of adverse reactions in the Sacubitril Valsartan Sodium Tablets treatment group was 10.0%,compared with 12.5% in the conventional treatment group,and there was no significant difference (P>0.05).Conclusion:The effect of Sacubitril Valsartan Sodium Tablets in the treatment of chronic heart failure is good,it can effectively improve the level of cardiac function and serological indicators,and does not increase the risk of drug use,it has good safety and high clinical application value.